Novo Nordisk's US Insurance Stalemate Casts Shadow Over Growth Plans

Major insurers decline or hesitate on BALANCE program, a blow to Novo Nordisk's US weight-loss drug expansion. Stock plunges amid competitive pressure from Eli Lilly and looming 2026 profit decline.

A critical deadline for a major US drug coverage program has passed without the necessary commitments from health insurers, dealing a blow to Novo Nordisk's near-term growth strategy. The BALANCE program, designed to expand Medicare coverage for GLP-1 weight-loss drugs starting in 2027, required insurers to signal participation by April 20. CVS Health formally declined, UnitedHealth expressed structural concerns, and other major providers remained silent, throwing the initiative's future into doubt.

This setback compounds existing pressures on the Danish pharmaceutical giant. The company's stock has shed roughly a quarter of its value since the start of the year and trades approximately 52% below its 52-week high. With a Relative Strength Index reading of 24.6, the shares are technically deep in oversold territory, reflecting widespread investor anxiety.

Competitive dynamics in the lucrative obesity drug market are intensifying simultaneously. Eli Lilly, which now commands over 60% of the US market for GLP-1 obesity medications, received FDA approval in early April for its oral drug Foundayo. The pill can be taken at any time of day without restrictions. In its first week, it garnered about 1,390 prescriptions. Novo Nordisk's oral Wegovy pill, which requires a morning dose on an empty stomach 30 minutes before eating or drinking, recorded 3,071 prescriptions in its launch week in January.

Novo Nordisk has countered with data from a cross-trial comparison, indicating Foundayo led to therapy discontinuations due to side effects approximately 14 times more frequently. Its own oral Wegovy achieved an average weight reduction of 16.6% in studies, compared to 12.4% for Foundayo.

The company's financial outlook for 2026 already anticipates a decline. Management forecasts a 5% to 13% drop in both revenue and operating profit, adjusted for currency effects. Contributing factors include reduced Medicaid reimbursements and the loss of exclusivity for semaglutid in some markets. Starting January 1, 2027, Novo Nordisk will also slash list prices for Wegovy and Ozempic by approximately 50% and 35%, respectively, to $675 each. Concurrently, a new Medicare price negotiated by CMS will take effect, setting the cost for a 30-day supply of semaglutid at $274—a 71% discount.

Amid these commercial headwinds, Novo Nordisk is pursuing strategic initiatives on other fronts. In mid-April, the company announced a partnership with OpenAI to integrate artificial intelligence across its business, from drug discovery to manufacturing. It is also providing shareholder returns through capital measures, with over DKK 60 billion earmarked for investors this year. A central component is a DKK 15 billion share buyback program launched in February, under which shares worth more than DKK 3 billion had been repurchased by mid-April.

For long-term growth, the pipeline candidate etavopivat for sickle cell disease remains a key prospect. Novo Nordisk plans to file for its first regulatory approval in the second half of 2026.

The immediate path forward, however, hinges on the US insurance landscape. The BALANCE program can only launch if a majority of major insurers participate. Without their backing, a key catalyst for Novo Nordisk's US sales growth is in jeopardy, leaving investors to weigh the support from buybacks against fundamental commercial pressures.